Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline.
HCV/HIV coinfection continues to represent a serious health issue with risk of liver disease progression and development of hepatocellular carcinoma. Pegylated interferon with ribavirin is approved for treatment but results are suboptimal and tolerability poor. First-generation HCV protease inhibitors appear to significantly improve HCV treatment response in the setting of HIV infection. Interactions with HIV protease inhibitors have been documented, but the significance of this in terms of adverse reactions and HCV or HIV viral breakthrough remains uncertain. Next generation agents hold the promise of even better efficacy, with improved dosing schedules and perhaps decreased risk of drug:drug interactions.
University of Cincinnati College of Medicine/UCHealth, 231 Albert Sabin Way, Cincinnati, OH 45267-0595, USA.
Carrie L
CL
Jennings
Kenneth E
KE
Sherman
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D060085:Coinfection; D018450:Disease Progression; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D016174:Hepacivirus / Q000201:enzymology; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D017093:Liver Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011480:Protease Inhibitors; D012367:RNA, Viral